Recent News

  • New financial analysis reveals significant savings realized from CYP2C19 testingTwenty lives and $440,000 over a year. For every 1,000 patients. That’s what CYP2C19 pharmacogenetic testing could save if used to help prescribe clopidogrel (Plavix), prasugrel or ticagrelor to specific cardiac patients. A budget analysis found that a genotype-guided approach for acute coronary syndrome patients (ACS) undergoing percutaneous coronary intervention ...Read More
  • 72 percent of heart drugs are impacted by genetics, study findsThe evidence for expanded use of pharmacogenetic data to help inform heart medication prescribing just got stronger. A comprehensive review of the scientific literature on pharmacogenomics and heart medications found that 71.8 percent of the 71 drugs studied had positive evidence for varied response or adverse effects based on genetics. ...Read More